Nipradilol Uses, Dosage, Side Effects & Benefits | DrugsAtlas
Authoritative Clinical Reference
DRUG NAME: Nipradilol
Therapeutic Class: Antiglaucoma Agent
Subclass: Non-selective Beta-blocker with α1-blocking and Nitric Oxide Donating Properties
Specialty: Ophthalmology
Schedule (India): Schedule H
Route(s): Ophthalmic
Formulations Available in India:
• Eye drops: 0.5% w/v
• Eye drops: 0.5% w/v
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
| Indication | Starting Dose | Titration | Maintenance Dose | Maximum Dose | Clinical Notes |
| Primary Open-angle Glaucoma | 1 drop of 0.5% in affected eye(s) twice daily | Not applicable; assess response at 2–4 weeks | 1 drop twice daily | 1 drop twice daily per eye | Onset of IOP reduction within 1–2 hours; maximum effect may require several weeks |
| Ocular Hypertension | 1 drop of 0.5% in affected eye(s) twice daily | Not applicable | 1 drop twice daily | 1 drop twice daily per eye | When combining with other topical antiglaucoma agents, maintain minimum 5–10 minute interval between instillations |
Administration Notes:
• Apply nasolacrimal occlusion for 1–2 minutes post-instillation to reduce systemic absorption
• May be used as monotherapy or in combination with prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-2 agonists
• Apply nasolacrimal occlusion for 1–2 minutes post-instillation to reduce systemic absorption
• May be used as monotherapy or in combination with prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-2 agonists
Secondary Indications — Adults (Off-label, if any)
Not applicable — No established off-label indications documented in Indian practice
PAEDIATRIC DOSING (Specialist Only)
Primary Indications:
• NOT APPROVED for routine paediatric use in India
• Safety and efficacy not established in children
• NOT APPROVED for routine paediatric use in India
• Safety and efficacy not established in children
Secondary Indications — Paediatrics (Off-label, if any):
| Age Group | Indication | Dose | Notes |
| ≥2 years | Developmental/juvenile glaucoma — OFF-LABEL | 0.5% eye drops, 1 drop twice daily | Specialist only; paediatric ophthalmologist supervision mandatory |
| <2 years | Not recommended | — | Avoid unless exceptional circumstances under tertiary centre protocol |
Safety Monitoring in Paediatrics:
• Monitor for systemic beta-blockade: bradycardia, bronchospasm, hypotension
• Heart rate assessment before and after initiation
• Nasolacrimal occlusion essential to minimize systemic absorption
• Not recommended below 18 years except under specialist supervision
• Limited Indian data available
• Monitor for systemic beta-blockade: bradycardia, bronchospasm, hypotension
• Heart rate assessment before and after initiation
• Nasolacrimal occlusion essential to minimize systemic absorption
• Not recommended below 18 years except under specialist supervision
• Limited Indian data available
RENAL ADJUSTMENT
• No dose adjustment required (topical ophthalmic administration with minimal systemic absorption)
HEPATIC ADJUSTMENT
| Child-Pugh Class | Recommendation |
| Class A (Mild) | No dose adjustment required |
| Class B (Moderate) | No dose adjustment required |
| Class C (Severe) | Use with caution; limited data; monitor for systemic beta-blockade effects; specialist supervision advised |
CONTRAINDICATIONS
• Known hypersensitivity to nipradilol or any formulation component
• Bronchial asthma or history of bronchial asthma
• Severe chronic obstructive pulmonary disease
• Sinus bradycardia (<50 beats per minute)
• Second-degree or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Decompensated heart failure
• Cardiogenic shock
• Bronchial asthma or history of bronchial asthma
• Severe chronic obstructive pulmonary disease
• Sinus bradycardia (<50 beats per minute)
• Second-degree or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Decompensated heart failure
• Cardiogenic shock
CAUTIONS
• Controlled chronic obstructive pulmonary disease — risk of bronchospasm
• Diabetes mellitus — may mask hypoglycaemic symptoms (tachycardia, tremor)
• Thyrotoxicosis — may mask tachycardia
• Myasthenia gravis — potential worsening of muscle weakness
• Peripheral vascular disease and Raynaud’s phenomenon
• Corneal disease — may reduce corneal sensitivity with prolonged use
• History of ocular surgery — monitor IOP closely
• Concurrent systemic beta-blockers — additive effects
• First-degree AV block — monitor for progression
• Abrupt discontinuation — avoid; may cause rebound effects
• Diabetes mellitus — may mask hypoglycaemic symptoms (tachycardia, tremor)
• Thyrotoxicosis — may mask tachycardia
• Myasthenia gravis — potential worsening of muscle weakness
• Peripheral vascular disease and Raynaud’s phenomenon
• Corneal disease — may reduce corneal sensitivity with prolonged use
• History of ocular surgery — monitor IOP closely
• Concurrent systemic beta-blockers — additive effects
• First-degree AV block — monitor for progression
• Abrupt discontinuation — avoid; may cause rebound effects
PREGNANCY
| Parameter | Details |
| Risk summary | Caution advised; no adequate human data; animal studies inconclusive |
| Preferred alternatives | Timolol (if beta-blocker required); brimonidine (safe in 2nd/3rd trimester) |
| When may be used | Only if benefit clearly justifies potential fetal risk; specialist supervision |
| Monitoring | Fetal growth; fetal heart rate if significant systemic absorption suspected; neonatal bradycardia and hypoglycaemia |
LACTATION
| Parameter | Details |
| Compatibility | Use with caution; likely minimal systemic absorption |
| Preferred alternatives | Timolol (more lactation safety data available) |
| Drug level in milk | Expected to be very low |
| Infant monitoring | Bradycardia, feeding difficulties, lethargy, inadequate weight gain |
| Administration advice | Apply nasolacrimal occlusion to reduce systemic absorption |
ELDERLY
• Starting dose: 0.5% eye drops, 1 drop twice daily (standard adult dosing)
• Titration: Not applicable for topical formulation
• Special considerations:
• Titration: Not applicable for topical formulation
• Special considerations:
- Slower systemic clearance generally not a major concern with topical use
- Monitor for systemic beta-blocking effects (bradycardia, hypotension) especially in frail patients
- Assess concurrent medications for additive effects
- Verify adequate manual dexterity for self-administration
- Punctal occlusion technique particularly important
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
| Systemic beta-blockers (atenolol, propranolol, metoprolol) | Additive beta-blockade; excessive bradycardia and hypotension | Avoid combination if possible; if essential, close monitoring of heart rate and blood pressure required |
| Verapamil, Diltiazem (systemic) | Increased risk of AV block and severe bradycardia | Avoid combination; specialist monitoring required if unavoidable |
| MAO inhibitors | Theoretical additive hypotensive effect | Avoid concurrent use |
| Clonidine | Risk of rebound hypertensive crisis on abrupt clonidine withdrawal | Taper clonidine gradually if discontinuing |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
| Other topical antiglaucoma agents | Additive IOP-lowering effect | May be used together; maintain 5–10 minute interval between instillations; monitor IOP |
| Insulin, sulfonylureas | Beta-blockade may mask hypoglycaemic symptoms | Monitor blood glucose; counsel diabetic patients |
| CNS depressants, sedatives | Potential additive bradycardic effect | Monitor heart rate |
| Digoxin | Additive bradycardia | Monitor heart rate and ECG |
COMMON ADVERSE EFFECTS
• Ocular stinging or burning on instillation
• Eye irritation
• Blurred vision (transient)
• Photophobia
• Dry eye sensation
• Foreign body sensation
• Conjunctival hyperaemia
• Headache
• Fatigue (rare, from systemic absorption)
• Eye irritation
• Blurred vision (transient)
• Photophobia
• Dry eye sensation
• Foreign body sensation
• Conjunctival hyperaemia
• Headache
• Fatigue (rare, from systemic absorption)
SERIOUS ADVERSE EFFECTS
• Symptomatic bradycardia — from systemic absorption; discontinue and refer
• Hypotension — from systemic absorption
• Bronchospasm — especially in predisposed individuals; discontinue immediately
• Corneal hypoesthesia — with prolonged use
• Severe allergic conjunctivitis or contact dermatitis — discontinue if suspected
• Severe ocular inflammation — discontinue and refer
• Syncope (rare)
• Worsening of heart failure (rare)
• Hypotension — from systemic absorption
• Bronchospasm — especially in predisposed individuals; discontinue immediately
• Corneal hypoesthesia — with prolonged use
• Severe allergic conjunctivitis or contact dermatitis — discontinue if suspected
• Severe ocular inflammation — discontinue and refer
• Syncope (rare)
• Worsening of heart failure (rare)
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Intraocular pressure, visual acuity, visual field assessment, optic nerve evaluation, heart rate and blood pressure (especially if cardiac comorbidities) |
| After initiation/dose change | IOP assessment at 2–4 weeks; evaluate tolerability and systemic effects |
| Long-term | IOP every 3–6 months; optic nerve status; corneal health; periodic heart rate and blood pressure (particularly in elderly or those on concurrent systemic beta-blockers) |
BRANDS AVAILABLE IN INDIA
• Hyprol Eye Drops (Centaur Pharma)
• Nionex Eye Drops (Sunways India)
• Nionex Eye Drops (Sunways India)
Note: Availability may be limited in certain regions; other generic brands under 0.5% strength may exist
PRICE RANGE (INR)
| Formulation | Approximate Price |
| 0.5% eye drops (5 mL) | ₹60–100 per bottle |
• Not included in NLEM; not under NPPA price control
• Availability variable across regions
• Private retail only
• Availability variable across regions
• Private retail only
CLINICAL PEARLS
• Triple mechanism (β-blockade + α1-blockade + NO donation) provides enhanced IOP lowering compared to conventional beta-blockers
• Useful in patients intolerant to traditional beta-blockers due to reduced systemic bradycardic effects from NO-donating property
• Consider for poor responders to monotherapy — may offer additional IOP reduction without class change
• Nocturnal IOP lowering may be modest; assess nighttime control if relevant
• Punctal occlusion technique essential to minimize systemic absorption, especially in elderly or patients with cardiac disease
• Counsel patients not to touch dropper tip to eye surface to prevent contamination
• Useful in patients intolerant to traditional beta-blockers due to reduced systemic bradycardic effects from NO-donating property
• Consider for poor responders to monotherapy — may offer additional IOP reduction without class change
• Nocturnal IOP lowering may be modest; assess nighttime control if relevant
• Punctal occlusion technique essential to minimize systemic absorption, especially in elderly or patients with cardiac disease
• Counsel patients not to touch dropper tip to eye surface to prevent contamination
TAGS
nipradilol; glaucoma; antiglaucoma; beta-blocker; alpha-blocker; nitric oxide donor; ophthalmic; ocular hypertension; Schedule H; topical; non-NLEM
VERSION
RxIndia v1.0 — 28 Feb 2026
REFERENCES
• CDSCO India
• Indian Pharmacopoeia / National Formulary of India
• AIIMS Pharmacology Internal Lists
• Indian Ophthalmology Specialist Prescribing Practice
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Available brand package inserts
• Indian Pharmacopoeia / National Formulary of India
• AIIMS Pharmacology Internal Lists
• Indian Ophthalmology Specialist Prescribing Practice
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Available brand package inserts
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.